Alpha Tau Medical Seeks Dual Listing on Tel Aviv Stock Exchange
Event summary
- Alpha Tau Medical Ltd. has filed for a dual listing on the Tel Aviv Stock Exchange (TASE), adding to its existing Nasdaq listing.
- The company aims to register 92,478,154 outstanding shares and up to 36,733,096 additional shares from convertible securities for TASE trading.
- Shares will trade under the symbol DRTS on both exchanges, with an alternative Hebrew symbol דרטס on TASE.
- Alpha Tau's Alpha DaRT technology is designed for treating solid tumors using alpha-radiation therapy.
The big picture
Alpha Tau's decision to list on TASE reflects a strategic pivot towards strengthening its presence in the Israeli market, capitalizing on growing local investor interest. This move aligns with broader trends of biotech companies seeking dual listings to enhance liquidity and investor base. The company's Alpha DaRT technology remains central to its valuation, as it continues to navigate the regulatory path for commercialization.
What we're watching
- Market Expansion
- How the dual listing will impact Alpha Tau's access to Israeli investors and local currency trading.
- Investor Sentiment
- Whether the move signals increased confidence in Alpha Tau's technology and growth prospects.
- Regulatory Compliance
- The pace at which Alpha Tau can navigate dual-listing regulatory requirements on both Nasdaq and TASE.
Related topics